c-FMS
c-Fms (colony-stimulating factor-1 receptor) is a sole receptor for M-CSF, and is a receptor tyrosine kinase.
Products for c-FMS
- Cat.No. Product Name Information
-
GC19404
AZD7507
AZD7507 is a potent and selective CSF-1R inhibitor (32 nM cell activity)
- GC12539 BLZ945 BLZ945 (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.
- GC34529 c-Fms-IN-1 c-Fms-IN-1 is a FMS kinase inhibitor with an IC50 of 0.0008 μM.
- GC35663 c-Fms-IN-10 c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM.
- GC66028 c-Fms-IN-13 c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor with an IC50 value of 17 nM. c-Fms-IN-13 can be used as an anti-inflammatory agent.
- GC35664 c-Fms-IN-3 c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent.
- GC35665 c-Fms-IN-8 c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM.
- GC35666 c-Fms-IN-9 c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC50s of <0.01 μM and 0.1-1 μM, respectively.
- GC34528 cFMS Receptor Inhibitor II cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor.
- GC65976 cFMS Receptor Inhibitor IV cFMS Receptor Inhibitor IV (Compound 42) is a potent cFMS inhibitor with an IC50 of 0.017 μM.
- GC31726 cFMS-IN-2 cFMS-IN-2 is a FMS kinase inhibitor with an IC50 of 0.024 μM.
- GC62145 Chiauranib Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects.
- GC33241 CSF1R-IN-1 CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
- GC64961 CSF1R-IN-2 CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.
- GC64805 CSF1R-IN-3 CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity.
- GC19418 Edicotinib Edicotinib is a selective and orally available colony-stimulating factor-1 (CSF-1) receptor inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease.
- GC31842 GENZ-882706 (RA03546849) GENZ-882706 (RA03546849) is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
- GC30295 GENZ-882706(Raceme) (GENZ-882706 racemate) GENZ-882706(Raceme) (GENZ-882706 racemate) is the racemate of GENZ-882706.
- GC17286 GW2580 CFMS kinase/CSF-1R inhibitor,selective and ATP-competitive
- GC13264 Ki20227 A c-Fms kinase inhibitor
- GC17958 Linifanib (ABT-869) Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis.
- GC66349 Mavrilimumab Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.
- GC14957 OSI-930 Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck
- GC12730 Pazopanib Hydrochloride VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor
- GC12222 Pexidartinib (PLX3397) Pexidartinib (PLX3397) (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX3397) (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX3397) (PLX-3397) induces cell apoptosis and has anti-tumor activity.
- GC34708 Pexidartinib hydrochloride Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity.
- GC36940 PLX5622 A CSF1R inhibitor
- GC38836 PLX5622 hemifumarate PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 ?M; Ki=5.9 nM).
- GC15075 PLX647 dual inhibitor of FMS and KIT kinases
- GC32802 PRN1371 An irreversible pan-FGFR inhibitor
-
GC69931
Sotuletinib hydrochloride
Sotuletinib (BLZ945) is an effective, selective, and brain-penetrant inhibitor of CSF-1R (c-Fms), with an IC50 of 1 nM and a selectivity that is 1000 times greater than other receptor tyrosine kinases.